These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22071129)

  • 21. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.
    Bensaïdane MR; Beauregard JM; Poulin S; Buteau FA; Guimond J; Bergeron D; Verret L; Fortin MP; Houde M; Bouchard RW; Soucy JP; Laforce R
    J Alzheimers Dis; 2016 Apr; 52(4):1251-62. PubMed ID: 27104896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid imaging in Alzheimer's disease and other dementias.
    Fodero-Tavoletti MT; Cappai R; McLean CA; Pike KE; Adlard PA; Cowie T; Connor AR; Masters CL; Rowe CC; Villemagne VL
    Brain Imaging Behav; 2009 Sep; 3(3):246-61. PubMed ID: 22005989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.
    Rabinovici GD; Jagust WJ
    Behav Neurol; 2009; 21(1):117-28. PubMed ID: 19847050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal Amyloid-β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration.
    Whitwell JL; Tosakulwong N; Weigand SD; Graff-Radford J; Duffy JR; Clark HM; Machulda MM; Botha H; Utianski RL; Schwarz CG; Senjem ML; Strand EA; Ertekin-Taner N; Jack CR; Lowe VJ; Josephs KA
    J Alzheimers Dis; 2020; 74(1):377-389. PubMed ID: 32039841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid imaging in dementias with atypical presentation.
    Wolk DA; Price JC; Madeira C; Saxton JA; Snitz BE; Lopez OL; Mathis CA; Klunk WE; DeKosky ST
    Alzheimers Dement; 2012 Sep; 8(5):389-98. PubMed ID: 22285638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice.
    Atri A
    Handb Clin Neurol; 2016; 136():971-84. PubMed ID: 27430453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid deposition in semantic dementia: a positron emission tomography study.
    Brown EE; Graff-Guerrero A; Houle S; Mizrahi R; Wilson AA; Pollock BG; Mulsant BH; Felsky D; Voineskos AN; Tang-Wai DF; Verhoeff NP; Freedman M; Ismail Z; Chow TW
    Int J Geriatr Psychiatry; 2016 Sep; 31(9):1064-74. PubMed ID: 26807731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.
    Rowe CC; Pejoska S; Mulligan RS; Jones G; Chan JG; Svensson S; Cselényi Z; Masters CL; Villemagne VL
    J Nucl Med; 2013 Jun; 54(6):880-6. PubMed ID: 23575995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET imaging of brain amyloid in dementia: a review.
    Quigley H; Colloby SJ; O'Brien JT
    Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.
    Cairns NJ; Ikonomovic MD; Benzinger T; Storandt M; Fagan AM; Shah AR; Reinwald LT; Carter D; Felton A; Holtzman DM; Mintun MA; Klunk WE; Morris JC
    Arch Neurol; 2009 Dec; 66(12):1557-62. PubMed ID: 20008664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Accuracy of Amyloid versus
    Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
    Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of [
    Lowe VJ; Lundt E; Knopman D; Senjem ML; Gunter JL; Schwarz CG; Kemp BJ; Jack CR; Petersen RC
    Neuroimage Clin; 2017; 16():295-302. PubMed ID: 28856092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA; Lopresti BJ; Venneti S; Price J; Klunk WE; DeKosky ST; Mathis CA
    Arch Neurol; 2009 Jan; 66(1):60-7. PubMed ID: 19139300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.